Literature DB >> 3038317

Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation.

L Giannone, S N Wolff.   

Abstract

A total of 16 patients with progressive CNS gliomas who had previously received maximal radiation therapy and chemotherapy were treated on a phase II study using high-dose etoposide with autologous bone marrow transplantation to assure hematopoietic recovery. Three patients (19%) responded with both improved neurological status and decreased mass on computerized tomographic scan. Median survival for all treated patients was 4 months with the three responders living 9, 10, and 54+ months.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3038317

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  9 in total

1.  High-dose etoposide: from phase I to a component of curative therapy.

Authors:  Steven N Wolff; John D Hainsworth; F Anthony Greco
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 3.  High dose chemotherapy for the treatment of malignant brain tumors.

Authors:  S H Petersdorf; R B Livingston
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma.

Authors:  T E Elliott; J C Buckner; T L Cascino; R Levitt; J R O'Fallon; B W Scheithauer
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

Review 5.  The expanding role of chemotherapy for pediatric supratentorial malignant gliomas.

Authors:  D C Lyden; W P Mason; J L Finlay
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

6.  Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.

Authors:  F B Cvitkovic; C Haie-Meder; V Papadimitrakopoulou; J P Armand; C Cioloca; N Maugis; J P Constans
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

7.  Penetration of etoposide into human malignant brain tumors after intravenous and oral administration.

Authors:  K Kiya; T Uozumi; H Ogasawara; K Sugiyama; T Hotta; T Mikami; K Kurisu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Recurrent brainstem gliomas treated with oral VP-16.

Authors:  M C Chamberlain
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

Review 9.  Chemotherapy for high-grade gliomas.

Authors:  E Galanis; J Buckner
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.